Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies. Recursion looks like a big dud so ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals (RXRX) closed the last trading session at $8.59, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher after the company announced a $50 million investment by NVIDIA Corporation (NASDAQ:NVDA), executed as a private investment in ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...